ÁñÁ«ÊÓƵ

This cohort study examines oncological outcomes after sentinel lymph node biopsy with dual-tracer mapping or targeted axillary dissection.

This randomized clinical trial evaluates outcomes among patients who received premastectomy radiotherapy and regional nodal irradiation followed by mastectomy and immediate breast reconstruction.

This nonrandomized clinical trial evaluates patient-reported outcomes in a clinical trial evaluating omission of breast surgery for invasive cancers with exceptional response to neoadjuvant systemic therapy.

This diagnostic study assesses the accuracy of post–neoadjuvant chemotherapy image-guided biopsy to predict residual cancer in the breast.

This phase 2 clinical trial of patients with recurrence of breast cancer in the ipsilateral breast assesses the effectiveness of partial breast reirradiation after a second lumpectomy.

This cohort study examines factors associated with lymphedema after neoadjuvant chemotherapy and axillary lymph node dissection in women with node-positive breast cancer.

This study of the National Cancer Database evaluated the association of nodal positivity rates with a pathologic complete response to neoadjuvant chemotherapy among patients with cT1/cT2 cN0 triple-negative breast cancer or ERBB2-positive disease.

This population-based cohort study evaluates the incidence of invasive breast biopsy during the 10-year follow-up of women with breast cancer

This cohort study identifies patients with breast cancer and a pathologic complete response to neoadjuvant chemotherapy with a low risk for axillary metastases and possibly eligible for omission of surgery.

This Special Communication examines the development of a standard set of value-based patient-centered outcomes for breast cancer.

This study investigates the long-term effect of axillary pathologic complete response on relapse-free and overall survival among women with breast cancer with cytologically confirmed axillary lymph node metastases treated with primary systemic chemotherapy.

This prospective feasibility trial adds selective removal of clip-containing lymph nodes to sentinel lymph node dissection, with the possibility of identifying patients for limited nodal surgery after chemotherapy.

Black et al determine racial differences in the use of sentinel lymph node biopsy among patients with pathologically node-negative breast cancer during the period when sentinel lymph node biopsy became the preferred method for axillary staging as well as whether such differences affect lymphedema risk. See the Invited Commentary by Murphy and Schulick.

Boughey and coauthors determine the false-negative rate for sentinel lymph node (SLN) surgery following chemotherapy in 663 women initially presenting with biopsy-proven node-positive breast cancer. In an Editorial, Morrow and Dang discuss false-negative rates and their role in determining whether to use more aggressive therapies.